Company intelligence / Profile preview

ReproNovo

Lausanne, Vaud, Switzerlandrepronovo.com ↗

Ownership: Private
Employees: ~50
Development stage: Preclinical

Overview

ReproNovo is advancing two clinical-stage assets. RPN‑001 (leflutrozole) is set to enter a Phase 2 trial for male infertility with hypogonadism, aiming to improve semen quality and pregnancy probability. RPN‑002 (nolasiban) will enter two Phase 2 trials—one for improving embryo implantation rates in women undergoing IVF and another for treating symptoms of adenomyosis. Both assets have prior clinical history from previous sponsors[4].

Therapeutic areas: Women's HealthMen's Health
Modalities: Small molecules (aromatase inhibitor, oxytocin receptor antagonist)[4][5]
Industry: Biotech

Drug pipeline

2 assets

nolasiban

1 more asset in the full pipeline.

Request access →

Partnerships

Mereo BioPharma (exclusive global license agreement for leflutrozole/RPN‑001)[6]

Beyond the preview

Go deeper on ReproNovo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ReproNovo.

Explore the full profile